

To,
The Editor-in-Chief
World Journal of Hepatology

26/06/2021

Subject: Response to reviewers and editorial comments for manuscript ID 66856-
Atezolizumab and Bevacizumab as first line therapy in Advanced Hepatocellular Carcinoma- “Practical Considerations in routine clinical practice”.

Dear Editor-in-Chief,

I am writing you to submit our responses to the reviewer's and editor's comments for the manuscript titled **Atezolizumab and Bevacizumab as first line therapy in Advanced Hepatocellular Carcinoma- “Practical Considerations in routine clinical practice”**, as a mini-review in the prestigious journal of World Journal of Hepatology.

Response to reviewer's comments:

1. Abstract: I recommend removing first sentence. There is some variability among references as to how HCC ranks worldwide in incidence and mortality, and some statistics may not clearly distinguish HCC versus primary liver cancer in regards to such statistics.

Response: We have deleted this sentence.

2. Abstract: For last sentence, consider that another purpose of this review is to highlight the current knowledge gaps and areas of active research.

Response: We have added this sentence in the abstract.

3. As this is a non-systematic review, it should be made clear in the introduction that this is an expert-based review. Like all expert-based reviews, this one may be prone to several biases related to the training/practice backgrounds of the authors, practice region, and literature selected/available for inclusion (e.g. English language only, etc).

Response: We have added a line to suggest that it is an expert review

4. Since the manuscript does appear to include some clinical recommendations, it should be made clear whether each recommendation is based on the author's opinion, evidence-based research or guideline, or clinical practice guideline. Additional references may be helpful to bolster some of the recommendations given.

Response: We have added references for ESMO and NCCN guidelines.

We have also added the recent update published by IMBrave150 investigators on the PROs benefits with atezolizumab and bevacizumab combination, the reference of article is number 9.

5. List of current/on-going studies aimed at addressing knowledge gaps:

Response: We have added a supplementary file listing all the current trials from NCI website currently in the active phases or inactive phases using the atezolizumab and bevacizumab combination in various phases.

Response to science editor's comments:

- 1. We have added DOI and PubMed number to most of the references.**
- 2. We have added article highlight section.**
- 3. We have meticulously reviewed the language of the article with “Grammarly” software.**

Sincerely,

Ankit Jain

Corresponding Author

Canberra Region Cancer Centre

The Canberra Hospital

Garran, ACT, 2606

Australia

Email: Ankit.Jain@anu.edu.au